Teva halts TOPAS-MSA trial after interim analysis meets futility threshold

Key Facts

Teva said it was stopping the Phase 2 TOPAS-MSA study of emrusolmin after a predictive interim analysis found a low likelihood of achieving the primary endpoint if the trial continued. The company said the analysis met the study’s prespecified futility threshold, prompting it to halt this clinical path. This was not a final efficacy analysis, and Teva said no safety concerns had been identified. The decision is limited to TOPAS-MSA and is not a final judgment on the broader emrusolmin program. The study was testing the treatment in people with multiple system atrophy, in a development program run by Teva in collaboration with MODAG GmbH.

According to the official ClinicalTrials.gov record, TOPAS-MSA was designed as a randomized, double-blind, placebo-controlled Phase 2 trial. Its status in the latest update posted before the halt announcement was “active, not recruiting.” The trial enrolled 349 participants, and researchers planned to follow each participant for 56 weeks. The plan included a 48-week double-blind treatment period, followed by a follow-up visit about 4 weeks after treatment ended. This design places the study’s results within an extended clinical follow-up, while the halt announcement remains tied to the futility criterion assessed by the interim analysis.

For participants outside the European Union, the primary endpoint was change from baseline in the modified UMSARS Part I, excluding item 11, through week 48. For participants in the European Union, the registry specified a different primary measure combining UMSARS Parts I and II. The difference means the endpoint was not uniform across the two geographic groups. However, Teva’s description of the analysis as predictive distinguishes the futility decision from a final assessment of change on these measures. The company did not announce a final efficacy result or a figure for the extent of change on the endpoint in the available information.

Teva said emrusolmin is a small molecule targeting alpha-synuclein and was under development in collaboration with MODAG GmbH. In an earlier announcement about the drug receiving Fast Track designation from the U.S. Food and Drug Administration, the company had noted that there were no available treatments that affect the progression of multiple system atrophy. This context underscores the importance of seeking potential development paths, but does not change the scope of the decision to stop TOPAS-MSA. The announced decision concerns this study, while Teva has not determined the fate of the broader drug program. The next steps cited by the company focus on a comprehensive analysis and data from the extension study, with no timing for their results specified in the available information.

Teva shares closed at $42.09 on October 30, compared with a close of $39.95 on October 26. These data predate the November 2 announcement that the study was being halted, so they do not measure the market’s reaction to the decision. The EL7 data available do not include a closing share price after the announcement. Teva is scheduled to report third-quarter 2026 results on November 3 and hold an investor call the same day at 8:00 a.m. Eastern Time. This may give the company a near-term opportunity to comment on its financial results, but the call’s timing alone does not indicate what it will announce about emrusolmin.